DNA Exome Sequencing TCM for Sjögren's Syndrome
Using the DNA Exome Sequencing Tools to Explore the Association Among Gene Sequence, TCM Pattern, TCM Tongue Diagnosis and TCM Pulse Diagnosis for Sjögren's Syndrome
1 other identifier
observational
40
1 country
1
Brief Summary
To explore the association among gene, TCM pattern, TCM tongue diagnosis and TCM pulse diagnosis with the DNA Exome sequencing tools for Sjögren's syndrome
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Apr 2019
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2019
CompletedFirst Submitted
Initial submission to the registry
April 22, 2019
CompletedFirst Posted
Study publicly available on registry
May 2, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 15, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2019
CompletedMay 6, 2019
May 1, 2019
1 month
April 22, 2019
May 2, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (7)
Immunity-related gene expression
To evaluate the immunity-related gene expression for the Sjögren's syndrome and healthy control. DNA exome combine the GATK (Genome Analysis Toolkit) is a tool for detecting the ratio of immunity-related gene expression.
One year
TCM pattern
To evaluate the difference of TCM pattern between Sjögren's syndrome and healthy control. TCM pattern is a tool for detecting the constitution.
One year
TCM tongue diagnosis
To evaluate the difference of TCM tongue diagnosis between Sjögren's syndrome and healthy control. TCM tongue diagnosis is a tool for detecting tongue expression.
One year
TCM pulse diagnosis
To evaluate the difference of TCM pulse diagnosis between Sjögren's syndrome and healthy control. TCM pulse diagnosis is a tool for detecting pulse of radial artery.
One year
Heart rate variability (HRV)
To evaluate the difference of Heart rate variability (HRV) between Sjögren's syndrome and healthy control. HRV is a tool for detecting the ratio between High-frequency (HF) activity and low-frequency (LF) activity.
One year
Immunity-related proteomics expression
To evaluate the proteomics for the Sjögren's syndrome and healthy control. Proteomics is a tool for detecting the ratio of immunity-related proteomics expression.
One year
Immunity-related microbiome expression
To evaluate the oral microbiome for the Sjögren's syndrome and healthy control. Oral microbiome is a tool for detecting the ratio of immunity-related microbiome expression.
One year
Study Arms (2)
Sjögren's syndrome
Sjögren's syndrome patients were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) primary or secondary SS; (2) aged between 20 and 75 years; (3) fulfilled the 2002 American-European Consensus Criteria for SS (AECG); (4) had no abnormal findings of immune, liver, kidney, or blood function evaluations. And the exclusion criteria were: (1) a history of alcohol abuse, diabetes mellitus, or major life-threatening condition; (2) pregnancy or breastfeeding; or (3) steroid pulse therapy within three months prior to the commencement of our study.
Health subjects
Health subjects were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital, and were enrolled with the inclusion criteria: (1) aged between 41 and 63 years (which the age could match the SS patients enrolling in the SS-1 trial); (2) had no chronic inflammatory illness. And the exclusion criteria were: (1) a history of alcohol abuse, diabetes mellitus, or major life-threatening condition; (2) pregnancy or breastfeeding; (3) abnormal findings of immune, liver, kidney, or blood function evaluations; (4) total sleeping time insufficiency less than 6 hours before one day of enrollment; (5) ever took the conventional medicine or hormone within one month; (6) ever encountered the acute illness, allergy reaction, immune, or rheumatic disease within one month.
Interventions
The DNA of Sjögren's syndrome patients and health subjects will take to do the DNA Exome sequencing.
The saliva of Sjögren's syndrome patients and health subjects will take to do the oral microbiome.
The protein of Sjögren's syndrome patients and health subjects will take to do the proteomics.
The RNA of Sjögren's syndrome patients and health subjects will store to do the RNA sequencing.
The serum of Sjögren's syndrome patients and health subjects will store to do the cytokine detection in the future.
Sjögren's syndrome patients and health subjects will take the Traditional Chinese Medicine pattern.
Sjögren's syndrome patients and health subjects will take the Traditional Chinese Medicine tongue diagnosis.
Sjögren's syndrome patients and health subjects will take the Traditional Chinese Medicine pulse diagnosis.
Sjögren's syndrome patients and health subjects will take the heart rate variability.
Sjögren's syndrome patients will take the Schirmer's test.
Sjögren's syndrome patients and health subjects will take the blood function test (WBC, RBC, Hb, HCT, Platelet, MCV, MCH, and MCHC), liver function test (AST and ALT), kidney function test (BUN and Cre), and immune function test (RF, Anti-SSA, Anti-SSB Ab, ESR, and CRP)
Eligibility Criteria
Sjögren's syndrome patients and Health subjects were screened in the rheumatology outpatient departments and Center for Traditional Medicine at Taipei Veterans General Hospital.
You may qualify if:
- (1) primary or secondary SS
- (2) aged between 20 and 75 years
- (3) fulfilled the 2002 American-European Consensus Criteria for SS (AECG)
- (4) had no abnormal findings of immune, liver, kidney, or blood function evaluations.
You may not qualify if:
- (1)a history of alcohol abuse, diabetes mellitus, or major life-threatening condition
- (2) pregnancy or breastfeeding
- (3) steroid pulse therapy within three months prior to the commencement of our study.
- Health Subjects
- (1) aged 20 and 75 years
- (2) had no chronic inflammatory illness.
- (1) a history of alcohol abuse, diabetes mellitus, or major life-threatening condition
- (2) pregnancy or breastfeeding
- (3) abnormal findings of immune, liver, kidney, or blood function evaluations
- (4) total sleeping time insufficiency less than 6 hours before one day of enrollment
- (5) ever took the conventional medicine or hormone within one month
- (6) ever encountered the acute illness, allergy reaction, immune, or rheumatic disease within one month.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Ching-Mao Chang
Taipei, Taiwan (r.o.c.), 112, Taiwan
Biospecimen
1. The DNA of Sjögren's syndrome patients and health subjects will take to do the DNA Exome sequencing. 2. The saliva of Sjögren's syndrome patients and health subjects will take to do the oral microbiome. 3. The protein of Sjögren's syndrome patients and health subjects will take to do the proteomics. 4. The RNA of Sjögren's syndrome patients and health subjects will store to do the RNA sequencing. 5. The plasma of Sjögren's syndrome patients and health subjects will store to do the cytokine detection in the future.
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Ching-Mao Chang, M.D., Ph.D.
Taipei Veterans General Hospital, Taiwan
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 22, 2019
First Posted
May 2, 2019
Study Start
April 1, 2019
Primary Completion
May 15, 2019
Study Completion
December 31, 2019
Last Updated
May 6, 2019
Record last verified: 2019-05
Data Sharing
- IPD Sharing
- Will not share